The FDA drug approvals database lists a supplemental application for a generic clozapine product from Mylan, dated 2 October 2026. The entry names the application and manufacturer only. It does not say whether the change concerns labelling, manufacturing or something else.
Supplements to generic applications are frequently administrative. Nothing in the record indicates a new safety communication or a change in how clozapine should be prescribed or monitored. The regulator and the authority cited here is the US FDA; this does not establish anything about the product's availability or status with the Indian regulator.
Prescribers who use this product can check the current label for changes before assuming anything has moved. The notice itself gives no information about monitoring requirements.
- FDA recorded a supplement to a generic clozapine application on 2 October 2026.
- The record does not state what changed.
- Check the current product label if you dispense or prescribe this product.
- The notice says nothing about monitoring or prescribing.
Why it matters
It is a reminder that a regulatory entry is not the same as a safety signal.
Don't overread it
A supplement to a generic application is not a new indication or a safety warning.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for psychiatry, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free